羟氯喹减量或停用后不良结局的预测因素:SLE治疗能否个体化决策
研究纳入5个加拿大SLE队列(1999–2019),评估羟氯喹减量或停用后复合不良结局的发生率及预测因素。减量队列不良结局率为35.7/100人年,停用队列为29.0/100人年,维持队列为16.1/100人年。减量时基线泼尼松使用、停用者中黑人及≤25岁诊断者与不良结局风险升高相关。
要点
- HCQ减量后不良结局率35.7/100人年,停用后29.0/100人年,均高于维持组的16.1/100人年。
- 减量患者中基线泼尼松使用与不良结局风险独立相关。
- 停用患者中黑人和≤25岁诊断SLE者不良结局风险更高。
核心结论
- 研究识别出与HCQ减量或停用后不良结局相关的人口学和临床因素,可用于药物短缺时及长期个体化治疗决策。
研究设计与样本
- 研究5个加拿大SLE队列(1999–2019),分别随访从HCQ减量(队列1,n=398)、停用(队列2,n=395)及维持治疗(队列3,n=395)的患者。
- 采用多变量Cox回归识别与复合结局(需强化治疗、SLEDAI-2K评分增加至少4分或SLE住院)时间相关的因素。
主要发现
- 不良结局率每100人年:减量队列35.7(95%CI 31.6–40.3),停用队列29.0(95%CI 25.5–33.0),维持队列16.1(95%CI 13.2–19.6)。
- 减量患者中基线泼尼松使用与不良结局风险独立相关。
- 停用患者中黑人和诊断SLE时年龄≤25岁者不良结局风险更高。
- 维持HCQ患者中基线免疫抑制剂使用和First Nations族裔与不良结局相关。
临床怎么用
- 在HCQ减量或停用前,应评估基线泼尼松使用、黑人种族及≤25岁诊断等风险因素以辅助个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hydroxychloroquine (HCQ) is a key systemic lupus erythematosus (SLE) drug, making concerns of drug shortages grave. Our objective was to evaluate factors associated with poor outcomes after HCQ taper or discontinuation in SLE. METHODS: We studied 5 Canadian SLE cohorts between 1999 and 2019, following patients from the date of HCQ tapering (cohort 1) or discontinuation (cohort 2). A composite outcome was defined as any of the following: a need for therapy augmentation, an increase (of at least 4 points) in the Systemic Lupus Erythematosus Disease Activity Index 2000 score, or hospitalization for SLE. In each cohort, multivariable Cox regression was used to identify demographic and clinical factors associated with time to the earliest of these events. A third cohort continuing to receive HCQ was also studied, to assess whether the same factors influenced the outcome even when the HCQ dose was unchanged. RESULTS: The poor outcome rate, per 100 person-years, was 35.7 (95% confidence interval [95% CI] 31.6-40.3) in the HCQ taper cohort (n = 398), 29.0 (95% CI 25.5-33.0) in the discontinuation cohort (n = 395), and 16.1 (95% CI 13.2-19.6) in the maintenance cohort (n = 395). In patients tapering HCQ, baseline prednisone use was independently associated with greater risk of poor outcomes. In the discontinuation cohort, the risk of poor outcomes was greater for Black patients and those diagnosed with SLE at age ≤25 years. Among those maintaining HCQ, baseline immunosuppressive use and First Nations ethnicity were associated with poor outcomes. CONCLUSION: We identified demographic and clinical factors associated with poor outcomes after HCQ taper/discontinuation. This information is critical in the current setting of potential shortages, but over the long term, such information could inform personalized therapies.
引用
- Almeida-Brasil CC, Pineau CA, Vinet E, et al. Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision-Making in Systemic Lupus Erythematosus Treatment? Arthritis Care Res (Hoboken). 2022. PMID: 33369255. doi:10.1002/acr.24548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。